NDAORALSOLUTION
Approved
Aug 1977
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
PAMELOR (nortriptyline hydrochloride) by ANI Pharmaceuticals is clinical pharmacology the mechanism of mood elevation by tricyclic antidepressants is at present unknown. Approved for depression. First approved in 1977.
Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PAMELOR (nortriptyline hydrochloride) is a tricyclic antidepressant approved in 1977 for the treatment of depression. It works by inhibiting the reuptake of catecholamines and interfering with the transport, release, and storage of neurotransmitters including norepinephrine and serotonin. The exact mechanism of mood elevation remains incompletely understood but involves both stimulant and depressant properties.
$2MPart D
LOE ApproachingDeclining
Product approaching loss of exclusivity with minimal Part D spending signals contraction; brand team focus likely shifting to cost management and generic transition planning.
Mechanism of Action
CLINICAL PHARMACOLOGY The mechanism of mood elevation by tricyclic antidepressants is at present unknown. Nortriptyline hydrochloride is not a monoamine oxidase inhibitor. It inhibits the activity of such diverse agents as histamine, 5-hydroxytryptamine, and acetylcholine. It increases the pressor…
Indications (1)
Career Relevance
PAMELOR positions represent stable but declining career opportunities within ANI Pharmaceuticals' mature product portfolio. Roles focus on supply chain efficiency, regulatory maintenance, and planned generic transition rather than innovation or expansion.
Worked on PAMELOR at ANI Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.